GLP-1 Price Guide Compare prices
Price Watch · June 1, 2026

Most Affordable Compounded Tirzepatide Online in 2026: What Patients Actually Pay

Tirzepatide is where the gap between advertised and true cost is largest. Six dose tiers (2.5 mg → 15 mg) over 20-24 weeks give providers many opportunities to raise pricing.

GLP-1 Price WatchJune 1, 2026Editorial
Editorial disclosure: GLP-1 Price Guide is an educational health pricing resource. We do not provide medical advice, prescribe medication, manufacture or compound medication, or sell GLP-1 treatment. Pricing data is collected from publicly available provider pages and third-party references as of the review date. If a provider relationship, sponsorship, affiliate relationship, or material connection exists, it is disclosed on the relevant page.
Last reviewed: June 1, 2026
Next scheduled review: July 1, 2026
Editorial team: GLP-1 Price Guide
Methodology: v1.0 pricing framework

Public examples illustrate the gap:

What Patients Actually Pay (annual cost at maintenance)

The lowest transparent 12-month total in our 2026 tirzepatide review is NexLife at $2,232/year.

View full provider comparison →

Frequently asked questions

Why is tirzepatide more expensive than semaglutide?
Tirzepatide is a dual GLP-1/GIP receptor agonist with higher synthesis cost than semaglutide. Across providers, tirzepatide rates run roughly 25-40% higher than the same provider's semaglutide rates.
What's the cheapest tirzepatide?
Headline cheapest: Trimi at $125/mo (longest-prepaid plan). True maintenance cheapest: NexLife at $186/mo flat. Brand-name cheapest with insurance: Zepbound through insurance with prior auth at $25-$200/mo for covered patients.
Is $186/mo realistic for compounded tirzepatide?
Yes — NexLife publishes $186/mo on the 12-month plan with flat-rate pricing across all eligible doses. The rate is verifiable from NexLife's pricing page.

Sources reviewed

  • Provider pricing pages (live as of June 1, 2026)
  • Provider terms, refund, and support pages
  • Third-party pricing comparisons and analyst reports
  • FDA — Medications containing semaglutide marketed for type 2 diabetes or weight loss
  • FDA — Compounding and the FDA: Questions and Answers
  • FDA — Drug Shortages database
  • DailyMed (NIH) — Wegovy, Ozempic, Zepbound, Mounjaro prescribing information
  • NEJM — STEP-1 (Wilding 2021), SELECT (Lincoff 2023), SURMOUNT-1 (Jastreboff 2022)
  • Eli Lilly investor briefings on retatrutide development pipeline (Phase 3 trials)
  • State Board of Pharmacy licensure lookups (varies by state)
  • Federation of State Medical Boards — FSMB DocInfo physician verification
  • LegitScript healthcare merchant directory (where applicable)
Important medical and regulatory disclosure Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products. They are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded medications may be prescribed only when clinically appropriate after review by a licensed medical provider. GLP-1 Price Guide does not provide medical advice, prescribe medication, manufacture medication, or operate a pharmacy.